Source comparison
CJC-1295 no DAC & Ipamorelin for Men: Comparison of Protocol Variables
Mechanism of Action GHRH receptor agonist. Extends natural GH pulse duration by amplifying pituitary response to endogenous GHRH Ghrelin receptor agonist. Triggers immediate pulsatile GH release independent of GHRH pathway Dual-pathway activation: one primes,
This comparison does not assign a generated winner or score.
- Mechanism of Action
- GHRH receptor agonist. Extends natural GH pulse duration by amplifying pituitary response to endogenous GHRH
- Ghrelin receptor agonist. Triggers immediate pulsatile GH release independent of GHRH pathway
- Dual-pathway activation: one primes, one triggers. Produces 3–5× higher GH peaks than mono-therapy
- Half-Life
- ~8 days (allows 1–2x weekly dosing)
- ~2 hours (requires multiple daily doses for sustained effect)
- Extended upstream priming + frequent downstream pulses = wider AUC
- Dosing Frequency (Research)
- 100–200 mcg, 1–2 times per week
- 200–300 mcg, 1–3 times daily (fasted state)
- Staggered dosing maintains elevated GH for 24+ hours per day
- Side Effect Profile
- Minimal. No cortisol or prolactin elevation; rare injection site reactions
- Minimal. No cortisol spike (unlike GHRP-6); transient hunger possible
- Lower adverse event rate than synthetic GH administration
- Reconstitution Requirement
- Bacteriostatic water; stable 28 days at 2–8°C post-reconstitution
- Both require identical cold-chain handling. Simplifies lab workflow
- Professional Assessment
- Best-in-class GHRH analogue for research contexts where sustained GH elevation without cortisol interference is critical
- Most selective ghrelin mimetic available. Triggers GH without appetite or cortisol confounds
- The combination is the gold standard for male GH research because it replicates physiological pulsatility better than exogenous GH